FDA Budget Issues Creep Into Strategic Priorities
This article was originally published in The Rose Sheet
Executive Summary
“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says. Agency officials included stewardship, such as doing more with less funding, among the cross-cutting strategic priorities in its draft strategic priorities document for 2014-2018.
You may also be interested in...
Congressional Appropriators Urge FDA Action On Cosmetic Lead Limits
House and Senate committee reports on proposed FDA appropriations for fiscal 2015 direct the agency to respond to a nearly three-year-old petition requesting an agency-sanctioned limit on trace lead in lipstick and other cosmetics. Appropriators set a March 15, 2015 deadline for FDA’s response.
FDA Committed To Advancing Its Regulatory Science Capacity
FDA cites "advances in the application of nanotechnology" among scientific "breakthroughs" that are revolutionizing the health-care community's ability to treat disease, making the notion of personalized care a reality and demanding more FDA involvement
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.